3rd Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$260,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

12 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Support full funding across HHS departments

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Health Issues HCR

Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support legislation providing Medicare coverage for anti-obesity medication Submit comments with regards to CMS' MDPNP guidance for IPAY28

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Oppose Most Favored Nations Executive Order

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Natl Institute of Standards & Technology (NIST); SENATE

Manufacturing MAN

Support robust domestic supply chain development and manufacturing ecosystem

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Labor Issues/Antitrust/Workplace LBR

Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Small Business SMB

Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Small Business Administration (SBA)

Science/Technology SCI

Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: HOUSE OF REPRESENTATIVES

Tariff (miscellaneous tariff bills) TAR

Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries

LobbyistCovered position, as disclosed
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.